RESPONSE TO INTRAVITREAL AFLIBERCEPT IN A PATIENT WITH PERIPHERAL EXUDATIVE HEMORRHAGIC CHORIORETINOPATHY

Retin Cases Brief Rep. 2021 May 1;15(3):286-288. doi: 10.1097/ICB.0000000000000787.

Abstract

Purpose: To draw attention to a novel treatment agent for vision loss associated with peripheral exudative hemorrhagic chorioretinopathy.

Methods: The case of an 83-year-old man suffering with loss of left visual acuity vision in the context of vitreous hemorrhage secondary to peripheral exudative hemorrhagic chorioretinopathy is described.

Results: Resolution of vitreous hemorrhage and subretinal hemorrhage was demonstrated after treatment with aflibercept.

Conclusion: Peripheral exudative hemorrhagic chorioretinopathy is discussed in terms of its presentation, pathophysiology, and existing treatment methodologies.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Angiogenesis Inhibitors / therapeutic use*
  • Central Serous Chorioretinopathy / diagnosis
  • Central Serous Chorioretinopathy / drug therapy*
  • Central Serous Chorioretinopathy / physiopathology
  • Exudates and Transudates
  • Humans
  • Intravitreal Injections
  • Male
  • Receptors, Vascular Endothelial Growth Factor / therapeutic use*
  • Recombinant Fusion Proteins / therapeutic use*
  • Retinal Hemorrhage / diagnosis
  • Retinal Hemorrhage / drug therapy*
  • Retinal Hemorrhage / physiopathology
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology
  • Vitreous Hemorrhage / diagnosis
  • Vitreous Hemorrhage / drug therapy*
  • Vitreous Hemorrhage / physiopathology

Substances

  • Angiogenesis Inhibitors
  • Recombinant Fusion Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • aflibercept
  • Receptors, Vascular Endothelial Growth Factor